TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03986359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
Study: NCT03835559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate closure
Description: After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate closure
Description: After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stripping
Description: All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical stripping
Description: All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
Study: NCT03498690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive
Description: Stakeholder groups: a=\> b
Study: NCT03138889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be dosed per the pharmacy manual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be dosed per the pharmacy manual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be dosed per the pharmacy manual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel will be dosed per local practice and label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be dosed per local practice and label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be dosed per the pharmacy manual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be dosed per current label indication
Study: NCT04164446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo that will be used contains starch and glucose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil Palm Phenolics
Description: One capsule contains 250 mg OPP or 1 g OPP
Study: NCT04347213

Intervention type: BEHAVIORAL
Intervention: Regular lifestyle in different circumstances
Description: Participants' lifestyle will be followed over the years.

Intervention type: BEHAVIORAL
Intervention: Regular lifestyle in different circumstances
Description: Participants' lifestyle will be followed over the years.

Intervention type: BEHAVIORAL
Intervention: Regular lifestyle in different circumstances
Description: Participants' lifestyle will be followed over the years.
Study: NCT01934660

Intervention type: DRUG
Intervention: 13N-amonia

Intervention type: DRUG
Intervention: 13N-amonia

Intervention type: DRUG
Intervention: 13N-amonia
Study: NCT04851392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Description: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
Study: NCT01186679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laminectomy
Description: surgical laminectomy with glial scar resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal
Description: direct into the CSF through lumbar puncture
Study: NCT02259582

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: demcizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: demcizumab
Study: NCT04164446

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil Palm Phenolics
Description: One capsule contains 250 mg OPP or 1 g OPP

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil Palm Phenolics
Description: One capsule contains 250 mg OPP or 1 g OPP
Study: NCT01015872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
Study: NCT00949117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Given orally
Study: NCT00584090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate (VESIcare)
Description: 5 - 10 mg po qd for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent of 5-10 mg po qd for 1 month
Study: NCT01053728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR161271
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT01598558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64 Rituximab
Description: Up to 14 mCi, iv
Study: NCT04851392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis with THC without CBD
Description: Cannabis with THC without CBD - inhaled and vaporised cannabis flower

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cannabis
Description: Placebo cannabis, without THC and without CBD - inhaled and vaporised
Study: NCT00713349

Intervention type: DRUG
Group type: OTHER
Intervention: Xenaderm Vehicle
Description: Ointment to be applied three times a day on cryo-surgery wound for 21 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Ointment to be applied three times a day on cryo-surgery wound for 21 days.
Study: NCT02706275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External warming
Description: External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
Study: NCT04301479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone sodium succinate
Description: Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
Study: NCT01163357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT02788227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV-Zebov GP vaccine
Description: primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV-Zebov GP vaccine
Description: primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
Study: NCT01741883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Side effect prevention training (SEPT)
Description: SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control group (ACG)
Description: Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
Study: NCT01069874

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D/Vigantol oil)
Description: Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol oil
Description: Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
Study: NCT01189786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent system
Description: A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
Study: NCT01053728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR161271
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR161271
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT01189786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent system
Description: A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent system
Description: A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
Study: NCT04077190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells
Description: 5cc adipose derived stem cells.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cortisone injection
Description: cortisone injection
Study: NCT01053728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT01163357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo TMI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03458260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone
Description: 6 cycles - dose = 80mg/m²

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 6 cycles - 1500 mg/m2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 6 cycles - 150 mg/m2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 6 cycles - 375 mg/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: after 2 or 6 cycles
Study: NCT03037398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vercise Deep Brain Stimulation System

Intervention type: DEVICE
Group type: OTHER
Intervention: Vercise Deep Brain Stimulation System
Study: NCT01374984

Intervention type: BIOLOGICAL
Intervention: VIGIV
Description: VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
Study: NCT01969786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal ulcer prevention program
Description: The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
Study: NCT01596309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa extract
Description: Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract
Description: Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
Study: NCT03813615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill walking (Proof-of-Concept)
Description: Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill walking Dose-Finding / Escalation
Description: Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
Study: NCT02974712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT04060095

Intervention type: PROCEDURE
Intervention: standardized noxious stimulus under general anesthesia.
Description: 50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient.
Study: NCT01363882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep study-guided adjustment of NIV
Description: Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard initiation of NIV
Description: NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
Study: NCT02537587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control 1
Description: 67g of control bar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control 2
Description: 86g of control bar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15/0
Description: 66g of experimental bar 15/0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15/0LS
Description: 84g of experimental bar 15/0LS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15/5
Description: 75g of experimental bar 15/5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10/5
Description: 72g of experimental bar 10/5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10/10
Description: 80g of experimental bar 10/10